GGrantIndex
← Leaderboards

Matthew J Wolf

Duke University

$7,663,961
Attributed
$10,683,909
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY200725
$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,683,909 · 6

By mechanism

R01$9,608,659 · 4
K08$631,125 · 1
R21$444,125 · 1

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Signal Transduction

Research focus

Signal TransductionHeart FailureSignal PathwayCardiovascular DiseasesIn VivoAdultCardiac MyocytesCellsBaseGeneticMortalityInnovationCardiacInvestigationMorbidity - Disease RatePathway InteractionsKnock-OutMolecularMyocardiumMouse ModelLeadHeart FunctionGenesCardiomyopathies

Grant awards (26)

Systems Pharmacology Model of Cardiac Hypertrophy$761,655
R01 · FY2025 · HL
Multiparametric MRI for the investigation of coronary microvascular disease$759,343
R01 · FY2025 · HL
Multiparametric MRI for the investigation of coronary microvascular disease$766,414
R01 · FY2024 · HL
Systems Pharmacology Model of Cardiac Hypertrophy$746,423
R01 · FY2024 · HL
DYRK1a as a therapeutic target to treat myocardial infarction$403,750
R01 · FY2024 · HL · contact PI
Diversity Supplement: Systems Pharmacology Model of Cardiac Hypertrophy$50,330
R01 · FY2024 · HL
Multiparametric MRI for the investigation of coronary microvascular disease$783,404
R01 · FY2023 · HL
Systems Pharmacology Model of Cardiac Hypertrophy$761,655
R01 · FY2023 · HL
DYRK1a as a therapeutic target to treat myocardial infarction$403,750
R01 · FY2023 · HL · contact PI
A CRISPR-based modular transgenic system to advance in vivo investigations of angiogenesis and fibrosis$201,875
R21 · FY2023 · OD · contact PI
Systems Pharmacology Model of Cardiac Hypertrophy$761,655
R01 · FY2022 · HL
Multiparametric MRI for the investigation of coronary microvascular disease$649,018
R01 · FY2022 · HL
DYRK1a as a therapeutic target to treat myocardial infarction$403,750
R01 · FY2022 · HL · contact PI
A CRISPR-based modular transgenic system to advance in vivo investigations of angiogenesis and fibrosis$242,250
R21 · FY2022 · OD · contact PI
DYRK1a as a therapeutic target to treat myocardial infarction$403,750
R01 · FY2021 · HL · contact PI
Novel pathways modulating Raf-mediated cardiac hypertrophy$395,000
R01 · FY2017 · HL · contact PI
Novel pathways modulating Raf-mediated cardiac hypertrophy$395,000
R01 · FY2016 · HL · contact PI
Novel pathways modulating Raf-mediated cardiac hypertrophy$238,882
R01 · FY2015 · HL · contact PI
Novel pathways modulating Raf-mediated cardiac hypertrophy$147,730
R01 · FY2015 · HL · contact PI
Novel pathways modulating Raf-mediated cardiac hypertrophy$384,650
R01 · FY2014 · HL · contact PI
Novel pathways modulating Raf-mediated cardiac hypertrophy$392,500
R01 · FY2013 · HL · contact PI
Genetic modifiers of dilated cardiomyopathy in adult Drosophila$126,225
K08 · FY2011 · HL · contact PI
Genetic modifiers of dilated cardiomyopathy in adult Drosophila$126,225
K08 · FY2010 · HL · contact PI
Genetic modifiers of dilated cardiomyopathy in adult Drosophila$126,225
K08 · FY2009 · HL · contact PI
Genetic modifiers of dilated cardiomyopathy in adult Drosophila$126,225
K08 · FY2008 · HL · contact PI
Genetic modifiers of dilated cardiomyopathy in adult Drosophila$126,225
K08 · FY2007 · HL · contact PI